EQRX aims for biopharma SPAC record

SPACs might be struggling to attract the interest they once did but the EQRX deal shows that this route to the stock market can still be hugely successful – in terms of raising money – if the right group of investors can be found. The developer will bank $1.8bn should the company’s combination with CM Life Sciences III close.